Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) just unveiled an update.
Lumos Diagnostics reported a steady revenue of US$3.4 million for the first quarter of FY26, with a notable 300% increase in product revenue driven by the adoption of FebriDx® in the U.S. The company secured a significant distribution agreement with PHASE Scientific and is awaiting feedback on a CLIA waiver submission for FebriDx. Lumos also continues its development projects, including an expanded agreement with Hologic for a next-generation diagnostic product, and has secured a loan facility to support its working capital needs.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd. is a leader in rapid point-of-care diagnostic technologies. The company specializes in developing and manufacturing diagnostic tests and custom reader development services. Lumos focuses on providing solutions for healthcare providers, with a significant market presence in the U.S. and collaborations with companies like Hologic.
Average Trading Volume: 6,515,562
Technical Sentiment Signal: Buy
Current Market Cap: A$169M
See more insights into LDX stock on TipRanks’ Stock Analysis page.